Janssen Pharmaceutical Cos.
www.janssen.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Janssen Pharmaceutical Cos.
Arcellx Raises $115m To Advance Novel T-Cell Therapies
The company’s first candidate is a BCMA-targeting CAR-T, but Arcellx also is developing ARC T-cells controlled by a synthetic protein. Both have a binding domain that may confer better safety and efficacy than competitors.
Coronavirus Notebook: Vaccine Shortage Fears Heightened By Safety Scares, Italian Jab Enters Phase II/III
Russia’s Sputnik V vaccine gets the all-clear in India as the COVAX initiative hits the shortages speed bump. Also, two more antibody treatments are OKd for use in COVID-19 in the UK.
Coronavirus Notebook: EMA Probes Janssen Vaccine Blood Clot Reports, UK Advises 12-Week Dosing Gap For Moderna
The AZ vaccine is now under EU scrutiny over capillary leak syndrome, while Valneva has reported positive results with its product. The global COVAX initiative has delivered more than 38 million doses of vaccines to over a hundred countries.
Brazil OKs Fourth COVID-19 Vaccine, But Knocks Back Bharat Biotech
Janssen’s Ad26.COV2-S is the latest COVID-19 vaccine to be authorized for emergency use in Brazil. The country’s drugs agency has also received an emergency use request from Lilly for its monoclonal antibody combination, banlanivimab and etesevimab, for treating COVID-19.
Company Information
- Industry
- Pharmaceuticals